

Overall Survival and Local Control of Hepatic Metastatic Lesions Treated with Stereotactic Body Radiotherapy

Open Access**Abstract**

Published 03/06/2024

Copyright

© Copyright 2024

Figon Muñoz et al. This is an open access abstract distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Distributed under

Creative Commons CC-BY 4.0

Crhys E. Figon Muñoz ¹, Francisco Lozano ², M Adela Poitevin Chacón ³

¹. Radiotherapy, UMAE 25, Monterrey, MEX ². Radiation Oncology, Medica Sur, Mexico City, MEX ³. Radiotherapy, Medica Sur, Mexico City, MEX

Corresponding author: Crhys E. Figon Muñoz, cfigon24@gmail.com**Categories:** Medical Physics, Radiation Oncology**Keywords:** stereotactic body radiotherapy**How to cite this abstract**

Figon Muñoz C E, Lozano F, Poitevin Chacón M (March 06, 2024) Overall Survival and Local Control of Hepatic Metastatic Lesions Treated with Stereotactic Body Radiotherapy. Cureus 16(3): a1143

Abstract

Objectives:

Determine the local control (LC) and overall survival (OS) rate in patients treated with hepatic stereotactic body radiotherapy (SBRT) from 2017 to 2022

Methods:

A retrospective review was performed from January 2017 to August 2022 of the 68 SBRT cases identified. Eleven patients were included in the analysis with: 1-5 metastases, unresectable, maximum diameter of 6 cm in single lesion or ≤10 cm in combination, oligometastatic or oligoprogressive disease, adequate liver function (Child Pugh A-B), life expectancy > 6 months and KPS 80-100.

Results:

11 patients with 19 hepatic metastases were included, with an average age of 66 years old. Median follow-up was 13 months. The mean number of lesions per patient was 2 with a mean PTV of 45.5cc. The most commonly used scheme was 50 Gy in 5 sessions of 10 Gy each, with a median BED of 87.3 Gy. OS at 1 and 2 years was 75%. LC at 1 and 2 years was 83% and 42%, respectively.

Conclusion(s):

The study confirms that SBRT in liver metastases is a safe and effective treatment with high control rates higher than 80% at one year with SBRT, so we believe it should be promoted in our environment in properly selected patients and with centers that have the technology to perform it.